BEBT-109 Drug Asset Due Diligence Report 2026

This BEBT-109 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether BEBT-109 can convert its Small molecule drug profile and EGFR L858R x EGFR T790M x EGFR exon 20 x EGFR-Ex19del x EGFR-G719X biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	BEBT-109 (query alias: BEBT-109)
Modality / target	Small molecule drug; EGFR L858R x EGFR T790M x EGFR exon 20 x EGFR-Ex19del x EGFR-G719X; EGFR T790M inhibitors, EGFR exon 19 deletion inhibitors, EGFR exon 20 inhibitors
Highest global status	Phase 2
Originator	BeBetter Med, Inc.
Active developers	BeBetter Med, Inc.

The MCP disease footprint includes Locally Advanced Lung Non-Small Cell Carcinoma, Non-squamous non-small cell lung cancer, EGFR ex20ins mutation in non-small cell lung cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06706713	Phase 2	Recruiting	200	Primary endpoint not disclosed in English source
NCT06514027	Phase 2	Recruiting	30	Primary endpoint not disclosed in English source
NCT06001671	Phase 1	Completed	23	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer

Not disclosed; n=29; evaluation: Not stated in English source. Reported fields: ORR = 44.4 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

BEBT-109 addresses Locally Advanced Lung Non-Small Cell Carcinoma, Non-squamous non-small cell lung cancer, EGFR ex20ins mutation in non-small cell lung cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned matched transaction record(s) under the scope “target-level comparable: EGFR L858R x EGFR T790M x EGFR exon 20 x EGFR-Ex19del x EGFR-G719X.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: EGFR L858R x EGFR T790M x EGFR exon 20 x EGFR-Ex19del x EGFR-G719X records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
No matched asset or comparable transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Ribonucleotide reductase (RNR) compositions and methods of use”. The milestone feed surfaced a patent-application signal described as “Combination therapy for treating abnormal cell growth”. The milestone feed surfaced a patent-application signal described as “Combination therapy for treating abnormal cell growth”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO